Literature DB >> 21963058

Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.

G B John Mancini1, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A Hegele, Dominic Ng, Janet Pope.   

Abstract

While the proportion of patients with significant statin-associated adverse effects or intolerance is very low, the increasing use and broadening indications have led to a significant absolute number of such patients commonly referred to tertiary care facilities and specialists. This report provides a comprehensive overview of the evidence pertaining to a broad variety of statin-associated adverse effects followed by a consensus approach for the prevention, assessment, diagnosis, and management. The overview is intended both to provide clarification of the untoward effects of statins and to impart confidence in managing the most common issues in a fashion that avoids excessive ancillary testing and/or subspecialty referral except when truly necessary. The ultimate goal is to ensure that patients who warrant cardiovascular risk reduction can be treated optimally, safely, and confidently with statin medications or alternatives when warranted.
Copyright © 2011 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963058     DOI: 10.1016/j.cjca.2011.05.007

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  46 in total

1.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

2.  Should Patients Continue to Receive Statins Once They Reach 80 Years of Age?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2017-06-30

3.  Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.

Authors:  Emmanuel Barrat; Yassine Zaïr; Pascal Sirvent; Patrice Chauveau; Corinne Maudet; Béatrice Housez; Elodie Derbord; Jean-François Lescuyer; Jean-Marie Bard; Murielle Cazaubiel; Sébastien L Peltier
Journal:  Eur J Nutr       Date:  2012-12-25       Impact factor: 5.614

Review 4.  Primary prevention of cardiovascular disease with statins in the elderly.

Authors:  Zeljko Reiner
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

5.  New Antilipid Drugs: Do the Known Benefits Justify the Expense?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2016-08-31

Review 6.  Statin-Associated Muscle Adverse Events: Update for clinicians.

Authors:  Maha A Al-Mohaissen; Martha J Ignaszewski; Jiri Frohlich; Andrew P Ignaszewski
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30

7.  Genealogical analysis as a new approach for the investigation of drug intolerance heritability.

Authors:  Marc Tremblay; Tarek Bouhali; Daniel Gaudet; Diane Brisson
Journal:  Eur J Hum Genet       Date:  2013-11-27       Impact factor: 4.246

Review 8.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

Review 9.  Treatment Options for Statin-Associated Muscle Symptoms.

Authors:  Ulrich Laufs; Hubert Scharnagl; Martin Halle; Eberhard Windler; Matthias Endres; Winfried März
Journal:  Dtsch Arztebl Int       Date:  2015-10-30       Impact factor: 5.594

Review 10.  Nutrition of the critically ill - emphasis on liver and pancreas.

Authors:  Stig Bengmark
Journal:  Hepatobiliary Surg Nutr       Date:  2012-12       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.